Skip to main content

Dr. Brian T. Hess, M.D.

Hematology (Hematology (Internal Medicine) Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2010
Medicare patients seen, 2024
274

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2010Medical school: University of Missouri, Columbia School of Medicine
  • 2010Registered with an NPI (national billing number; not a license date)

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology (Internal Medicine) Physician primary
    SC license 39373
  • Hematology & Oncology Physician
    MO license 2013015488 · SC license 39373
  • Internal Medicine Physician
    IL license 125-058489

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
274
Services billed
545
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes241153
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes11839
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes10239
New patient office or other outpatient visit, 60-74 minutes6464
Established patient office or other outpatient visit, 20-29 minutes4845
Established patient office or other outpatient visit, 40-54 minutes2522
Hospital discharge day management, more than 30 minutes1716

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Acyclovir
Other prescribers in Charleston, SC
78
Brukinsa (zanubrutinib)67
Allopurinol
Other prescribers in Charleston, SC
28
Prednisone
Other prescribers in Charleston, SC
21
Ondansetron Hcl
Other prescribers in Charleston, SC
16
Calquence (acalabrutinib maleate)15
Udenyca (pegfilgrastim-cbqv)14
Revlimid (lenalidomide)12

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 3 payments worth $4,167 in total to this clinician.

By type
Consulting Fee$4,115
Food and Beverage$52.12

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 3, 2025Gilead Sciences, Inc.
Dec 3, 2025
Consulting Fee
Company’s description;4274075;GTF;10584857
$2,060
Jun 12, 2025Incyte Corporation
Jun 12, 2025
Consulting Fee$2,055

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in South Carolina →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $132,079 in research payments for these studies, mostly to the institutions running them.

  • Trial of consolidation therapy following CD19 CAR T cell treatment for Relapsed Refractory DLBCL or
    Genentech, Inc.
  • A Phase 1/2, Open-Label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma.
    Genmab U.S., Inc.
  • Multiple part clinical trial of brentuximab vedotin in classical hodgkin lymphoma subjects
    Pfizer Inc.
  • A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
    Acerta Pharma LLC
  • M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated …
    AbbVie Inc.
  • A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
    AstraZeneca Pharmaceuticals LP
  • Polarix
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology clinicians in Charleston

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 2, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1770898900. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.